Details of the Drug Reposition

General Information of This Drug (ID: DMZ8AL8)

Drug Name
BB3   DMZ8AL8
Synonyms
3-(3,5-Dibromo-4-hydroxybenzoyl)-2-ethyl-N,N-dimethylbenzofuran-6-sulfonamide; 765317-71-3; 3-(3,5-DIBROMO-4-HYDROXY-BENZOYL)-2-ETHYL-BENZOFURAN-6-SULFONIC ACID DIMETHYLAMIDE; BB3; 3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethyl-N,N-dimethyl-1-benzofuran-6-sulfonamide; SCHEMBL4320310; AC1L9M79; 1t48; ZINC14881085; AKOS025404898; DB04142; AK174884; N,N-Dimethyl-2-ethyl-3-(3,5-dibromo-4-hydroxybenzoyl)benzofuran-6-sulfonamide; 3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethyl-N,N-dimethylbenzofuran -6-sulfonamide
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Graft-versus-host disease DIS0QADF 4B24 Phase 3 [1]
Cerebrovascular ischaemia DISFSDLO 8B1Z Phase 3 [2]
Congestive heart failure DIS32MEA BD10 Phase 3 [2]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of Angion Therapeutics.